Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

• Simon Rule,
• Martin Dreyling,
• Andre Goy,
• Georg Hess,
• Rebecca Auer,
• Brad Kahl,
• José-Ángel Hernández-Rivas,
• Keqin Qi,
• Sanjay Deshpande,
• Lori Parisi,
• Michael Wang

Affiliations

Simon Rule

Department of Haematology, Plymouth University Medical School, UK

Martin Dreyling

Department of Medicine III, Klinikum der Universität München, LMU, Germany

Andre Goy

Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA

Georg Hess

Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University, Mainz, Germany

Rebecca Auer

Centre for Haemato-Oncology, Barts Cancer Institute, London, UK

Brad Kahl

Department of Medicine, Washington University, St. Louis, MO, USA

José-Ángel Hernández-Rivas

Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain

Keqin Qi

Janssen Research & Development, Raritan, NJ, USA

Sanjay Deshpande

Janssen Research & Development, Raritan, NJ, USA

Lori Parisi

Janssen Research & Development, Raritan, NJ, USA

Michael Wang

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA